A Carboxyl-terminal Domain in Fibroblast Growth Factor (FGF)-2 Inhibits FGF-1 Release in Response to Heat Shock in Vitro*

(Received for publication, September 30, 1996, and in revised form, October 14, 1996)

Jianping Shi Dagger , Stanley Friedman and Thomas Maciag §

From the Department of Molecular Biology, Holland Laboratory, American Red Cross, Rockville, Maryland 20855

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

The fibroblast growth factor (FGF) prototypes, FGF-1 and FGF-2, lack a signal sequence, but both contain a nuclear localization sequence. We prepared a series of FGF-1 deletion mutants fused to the reporter gene, beta -galactosidase (beta -gal) and determined that a domain between residues 83 and 154 is responsible for FGF-1 cytosol retention in NIH 3T3 cells. Using a series of FGF-beta -gal chimeric proteins prepared by the shuffling of cassette-formatted synthetic FGF prototype genes, we were able to demonstrate that the nuclear localization sequence from the 5'-CUG region of FGF-2 is not able to direct the nuclear association of FGF-1 due to its inability to repress the function of the FGF-1 cytosol retention domain. We also observed that while the FGF-1:beta -gal chimera was released in response to heat shock, the FGF-2:beta -gal protein was not. Further, replacement of the FGF-1 cytosol retention domain with the corresponding domain from FGF-2 repressed the release of the chimeric protein. These data suggest that the specificity of the stress-induced secretion pathway for FGF-1 involves a carboxyl-terminal domain that is absent in FGF-2 and that the FGF-1 secretion pathway does not restrict the release of high molecular weight forms of FGF-1.


INTRODUCTION

The heparin-binding fibroblast growth factor (FGF)1 family currently consists of nine structurally related members with broad biological activities (1, 2), and the biological functions of the FGF gene family members are mediated through high affinity FGF receptors, which contain intrinsic tyrosine kinase activity (3). The FGF prototypes, FGF-1 (acidic) and FGF-2 (basic), lack a classical signal sequence for secretion through the conventional endoplasmic reticulum (ER)-Golgi apparatus, and the signal sequences present in other FGF gene family members contribute to their oncogenic potential (1, 2). Because the mitogenic potential of the FGF prototypes are mediated by the function of the FGF prototypes as exogenous proteins, it has been proposed that novel and unconventional secretory pathways may have evolved to regulate their activities as extracellular modifiers of biological responses (1, 2).

We have shown that FGF-1 is secreted from NIH 3T3 cell FGF-1 transfectants by a brefeldin A-insensitive, ER-Golgi-independent pathway in response to heat shock (4, 5). FGF-1 is released as a latent homodimer with reduced affinity for immobilized heparin (4), and both the mitogenic and heparin-binding activities of latent extracellular FGF-1 can be activated by reducing agents (5). Mutagenesis of Cys residues in FGF-1 enabled us to demonstrate that Cys30 is solely responsible for the formation of the FGF-1 homodimer (6). In addition, FGF-1 is a phosphatidylserine-binding protein (6), and FGF-1 at 42 °C is able to attain a molten globule character, which enables it to associate with acidic phospholipid membranes (7). In contrast, FGF-2 is also secreted by a brefeldin A-insensitive pathway (8), and, although the Cys30 residue is conserved between FGF-1 and FGF-2 (1, 2), FGF-2 neither forms a homodimer (9) nor is released in response to temperature stress in vitro (8). Because it is possible that the FGF prototypes are released by different unconventional pathways, we sought to study the release of the FGF prototypes using a strategy of molecular shuffling of four synthetic cassettes, each encoding domains from FGF-1 (10) and FGF-2 (11). This overlapping cassette shuffle strategy has previously enabled us to construct and express a variety of novel recombinant FGF-1:FGF-2 chimeric proteins and determine that residues 65-81 from FGF-2 significantly contribute to the heparin-dependent character of FGF-1 as an exogenous mitogen (11). We have utilized these constructs to obtain stable NIH 3T3 cell FGF-1:FGF-2 cassette shuffle transfectants and studied the intracellular locale and secretory potential of these constructs as beta -galactosidase (beta -gal) reporter gene fusion proteins. We report that the carboxyl-terminal half of FGF-1 (residues 84-154) is involved in cytosol retention and contributes to the ability of FGF-1 to be released in response to heat shock and that the corresponding domain in FGF-2 is responsible for the inability of FGF-2 to be released in response to temperature stress in vitro. Finally, we also report that there does not appear to be a molecular weight restriction for the size of FGF-1 released in response to temperature stress in vitro, and nuclear-associated FGF-1 does not have access to the FGF-1 secretory pathway.


EXPERIMENTAL PROCEDURES

Plasmid Construction

The construction of plasmids pXZ45 and pXZ55 were previously described (12). The plasmid pJS2, which contains residues 21-78 of the human FGF-1 gene, was constructed by ligating the 6673-base pair (bp) ScaI-EspI fragment of pXZ55 and the 3011-bp XmaI-EspI fragment of pXZ55 together. The ScaI digestion was partial, and both the ScaI and XmaI sites were filled in with Klenow fragment (Boehringer Mannheim). The plasmid pJS123, which contains residues 21-117 of the human FGF-1 gene, was constructed in four steps involving three intermediate constructs: pJS23temp, pJS23temp2, and pJS23temp3. The plasmid pJS23temp was constructed by ligating the BamHI fragment of pXZ55, which contains the beta -gal fragment, into the HindIII site of pDS90 (10). The ligation of the 5334-bp BamHI-SmaI fragment of pXZ55 and the BamHI-SnaBI fragment of pJS23temp, which contains residues 38-117 of the human FGF-1 gene, generated pJS23temp2. The ligation of the 2138-bp BglII-EspI fragment of pXZ55 and the 7591-bp BglII-EspI fragment of pJS23temp2 generated pJS23temp3. Finally, the pJS123 was generated by ligating the 7909-bp ScaI fragment of pJS23temp3 with the 1905-bp ScaI fragment of pXZ55.

The plasmid pJS5, which contains residues 28-154 of the human FGF-1 gene, was constructed by ligating the ScaI-NheI fragment of pXZ31 (12) and the 5702-bp ScaI-HindIII fragment of pXZ55 with the 3556-bp HindIII-NheI fragment of pXZ55. The plasmids pSF25 and pSF26 were constructed in a multistep process involving intermediate plasmids pSF20 and pSF21. The plasmid pSF20 was constructed by oligonucleotide mutagenesis. The resulting clone is similar to hstbeta :pMEXneo (13) except for five single base changes resulting in Cys30 right-arrow Ser (codon changes TGT right-arrow TCT), Phe36 right-arrow Ser (TTC right-arrow TCC), Glu63 right-arrow Asp (GAA right-arrow GAT), Cys97 right-arrow Ser (TGT right-arrow TCT), and Cys131 right-arrow Ser (TGC right-arrow TCC) mutations in the human FGF-1 open-reading frame (ORF). The plasmid pSF21 was constructed by filling in the annealed oligonucleotides 5'-TACAAGGGATCCTCAGG(G/A)AGTGGCCCCCGTTGCTA(G/C)AGTAGAGGAGTTTGGGCTT-3' and 5'-GGGAAATACGTAGTCGACCTCGAGACCACCATGGCTAATTACAAGAAGCCCAAAC-3' with DNA polymerase, digestion with SalI-BamHI, and ligation to the large SalI-BamHI fragment of pSF20. The oligonucleotide bases in parenthesis are 50% mixtures at C30S and F36S positions, and pSF21 contains the wild-type bases at these positions. The plasmid pSF25, which contains residues 21-39 and 77-154 of the human FGF-1 gene, was constructed by ligating annealed oligonucleotides sense, 5'-GATCCGCCAGTACTTGGC-3', and antisense, 5'-CATGGCCAAGTACTGGCG-3' (BamHI-NcoI ends), with the 3329-bp NcoI-KpnI fragment of pXZ55 and the large BamHI-KpnI fragment of pSF21. The plasmid pSF26, which contains residues 21-40 and 112-154 of the human FGF-1 gene, was constructed by ligating the annealed oligonucleotides antisense, 5'-CTTCTTGGATATAAG-3', and sense, 5'-GATCCTTATATCCAAGAAGCATG-3' (BamHI-SphI ends), with the 3222-bp SphI-KpnI fragment of pXZ55 and the BamHI-KpnI fragment of pSF21. The plasmid pJS9, which contains residues 21-81 of the human FGF-1 gene and residues 85-155 of the FGF-2 gene, was constructed in two steps. The plasmid pJS9temp was generated by ligating the PpuMI-AvaI fragment of pT70405 (11) and the large AvaI-NheI fragment of pT70405 with four annealed oligonucleotides: sense, 5'-GACCTGGGCAGAAAGCTATACTTTTTCTTC-3'; sense, 5'-CAATGTCTGCTAAGAGCAGTTTAAACCCCGGGAGTCTG-3'; antisense, 5'-CTAGCAGACTCCCGGGGTTTAAACTGCTCTTA-3'; and antisense, 5'-GCAGACATTGGAAGAAAAAGTATAGCTTTCTGCCCAG-3' (PpuMI-NheI ends). The plasmid pJS9 was made by ligating the 343-bp BspEI-SmaI fragment of pJS9temp and the 6663-bp BspEI-EspI fragment of pXZ55 with the EspI-SmaI fragment of pXZ55, which contains the beta -gal gene. The plasmid pJS22temp was constructed by ligating the 1038-bp NdeI-BclI fragment of pSK(-)SVTC (SV40 large T antigen ORF; a kind gift from Dr. Daniel Simmon) (14) and the 2900-bp BamHI-SacI fragment of pSK(-)SVTC with the NdeI-SacI fragment of the polymerase chain reaction product of pSK(-)SVTC generated with primers: sense, 5'-GCATAGAGCTCGGCGCGCCATGGATAAAGTTTTAA-3', and antisense, 5'-ACAGCCTGTTGGCATATGGTTT-3'. The plasmid pJS22 was constructed by ligating the 9775-bp AscI-BspEI fragment of pXZ55 and the AscI-BspHI fragment of pJS22temp, which contains the SV40T gene, with four annealed oligonucleotides: sense, 5'-CATGATGCTAATTACAAGAAGCCCAAACTCCTCTA-3'; sense, 5'-CTGTAGCAACGGGGGCCACTTCCTGAGGATCCTT-3'; antisense, 5'-CCGGAAGGATCCTCAGGAAGTGGCCCCC-3'; and antisense, 5'-GTTGCTACAGTAGAGGAGTTTGGGCTTCTTGTAATTAGCAT-3' (BspEI-BspHI ends). The plasmid pJS8temp was generated by ligation of the PpuMI-AvaI fragment of pTI70407 (11) and the large AvaI-NheI fragment of pTI70407 with four annealed oligonucleotides: sense, 5'-GACCTGGGCAGAAAGCTATACTTTTTCTTC-3'; sense, 5'-CAATGTCTGCTAAGAGCAGTTTAAACCCCGGGAGTCTG-3'; antisense, 5'-CTAGCAGACTCCCGGGGTTTAAACTGCTCTTA-3'; and antisense, 5'-GCAGACATTGGAAGAAAAAGTATAGCTTTCTGCCCAG-3' (PpuMI-NheI ends). The plasmid pJS8, which contains residues 21-117 of the human FGF-1 gene and residues 120-155 of the human FGF-2 gene, was constructed by ligation of three DNA fragments: the 343-bp BspEI-SmaI fragment of pJS8temp, the 6563-bp BspEI-EspI fragment of pXZ55, and the EspI-SmaI fragment of pXZ55. The plasmid pJS7, which contains residues 21-81 and 118-154 of the human FGF-1 gene and residues 85-120 of the human FGF-2 gene, was prepared by ligating the 6563-bp EspI-BspEI fragment of pXZ55 and the 3129-bp EspI-SphI fragment of pXZ55 with the 225-bp BspEI-SphI fragment of pTI70406 (11). The plasmid pJS14, which contains the NLS from the human FGF-2 gene, residues 21-81 from the human FGF-1 gene, and residues 85-155 from the human FGF-2 gene, was constructed by ligating the 4250-bp BamHI-HindIII fragment of pXZ104 (12), the 342-bp BamHI-PmeI fragment of pJS9, and the 5477-bp PmeI-HindIII fragment of pJS9. The plasmid pJS10 was constructed by ligating the NdeI-BamHI fragment of pET3C (15) with the NdeI-BglII fragment of the polymerase chain reaction product of pTI70301 (11) generated with the following primers: sense, 5'-TAACATATGGCAGCCGGGAG-3', and antisense, 5'-CTCAGATCTTCAGCTCTTAGCAGA3'. The plasmid pJS20temp was constructed by ligating the 6570-bp XhoI-EspI fragment of pJS14 and the NcoI-EspI fragment of pXZ55, which contains the beta -gal fragment, with the XhoI-NcoI fragment of the polymerase chain reaction product of pJS10 generated with the following primers: sense, 5'-GCAGCCTCGAGTTCCCACCGGTCCACT3', and antisense, 5'-CCATCTTCCTCCATGGCCAGGTAAC-3'.

The plasmid pJS20, which contains the NLS from the human FGF-2 gene, residues 1-85 from the human FGF-2 gene, and residues 82-154 from the human FGF-1 gene, was constructed by ligating the 6570-bp XhoI-EspI fragment of pJS20temp and the 3420-bp AgeI-EspI fragment of pJS20temp with four annealed oligonucleotides: sense, 5'-TCGAGGATCAAGACCTGGCCCGGGTGCAGCCGGGA-3'; sense, 5'-GCATCACCACGCTGCCCGCCTTGCCCGAGGATGGCGGCAGCGGCGCCTTCCCA-3'; antisense, 5'-CCGGTGGGAAGGCGCCGCTGCCGCCATCCTCGGGCAAGGCGGGCAGC-3'; antisense, 5'-GTGGTGATGCTCCCGGCTGCACCCGGGCCAGGTCTTGATCC-3' (AgeI-XhoI ends). The plasmid pJS30, which contains the sequence from the human FGF-2 gene starting from the upstream alternative CUG translational site, was constructed by ligating the NcoI-EspI fragment of pJS14 and the NcoI-XhoI fragment of pJS20 containing the amino-terminal half of human FGF-2 with the large XhoI-EspI fragment of pJS20. The plasmid pJS34, which contains residues 1-155 from the human FGF-2 gene, was constructed by ligating the 1699-bp ScaI-SalI fragment of pJS30 and the 8188-bp ScaI-AgeI fragment of pJS30 with four annealed oligonucleotides: sense, 5'-TCGACGGGACCATGGCAGCCGGGAGCATCACCACGCTGCC-3'; sense, 5'-CGCCTTGCCCGAGGATGGCGGCAGCGGCGCCTTCCCA-3'; antisense, 5'-CCGGTGGGAAGGCGCCGCTGCCGCCATCCTC-3'; and antisense, 5'-GGGCAAGGCGGGCAGCGTGGTGATGCTCCCGGCTGCCATGGTCCCG-3' (AgeI-SalI ends).

Cell Culture, Transfection, Immunofluorescence and X-Gal Staining

NIH 3T3 cells (American Type Culture Collection) were maintained in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) containing 10% (v/v) bovine calf serum (Hyclone), and 1 × antibiotic-antimycotic (Life Technologies). Transfection was performed using the CaPO4 transfection protocol according to the manufacturer's instructions (Stratagene) as described previously (12). Individual transfected clones were selected and expanded by growth in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) bovine calf serum, 1 × antibiotic-antimycotic, and 800 µg/ml geneticin (G418) (Life Technologies). Immunofluorescence was performed on NIH 3T3 cell transfectants grown on fibronectin-coated chamber slides (Nunc Inc.) as described previously (16). X-gal staining was performed on 70% confluent monolayers of NIH 3T3 cells transfected with the plasmid of interest as described previously (16).

Cell Fractionation, Immunoprecipitation, and Immunoblot Analysis

The subcellular fractionation of NIH 3T3 cell transfectants was performed as described previously (12). Briefly, the cells were scraped, centrifuged, and resuspended in 1 ml of buffer A (15 mM HEPES, pH 7.5, 300 mM sucrose, 60 mM KCl, 15 mM NaCl, 0.5 mM EDTA, 0.5% (v/v) Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and 2 µg/ml aprotinin). After incubation on ice for 10 min, the cells were centrifuged at 800 × g for 10 min at 4 °C. The supernatants were labeled as cytosol, and the nuclear pellets were resuspended in 1 ml of buffer A and centrifuged (800 × g, 10 min, 4 °C) through a 3-ml sucrose cushion (buffer A containing 350 mM sucrose). The nuclear pellets were resuspended in 1 ml of buffer A containing 0.4% (w/v) SDS, 8 mM MgCl2, and 10 units of DNase and incubated for 5 min at 37 °C followed by 15 min at room temperature. Both the nuclear and cytosol fractions were cleared by centrifugation (14,000 × g, 10 min, 4 °C).

Immunoprecipitation was performed by incubating either the cytosol or nuclear fractions with 1 µl of anti-beta -gal antibody (5 Prime right-arrow 3 Prime, Inc., Boulder, CO) and rotating for 1 h at 4 °C, followed by the addition of 20 µl of protein A-Sepharose CL-4B (50% (w/v); Pharmacia Biotech Inc.) and rotating for 1 h at 4 °C. The Sepharose beads were washed three times with radioimmune precipitation buffer (10 mM Tris, pH 7.5, containing 150 mM NaCl, 1% Triton X-100 (v/v), 1 mM EDTA, 0.5% (w/v) deoxycholic acid, 0.1% (w/v) SDS) and extracted with 20 µl of 2 × SDS-sample buffer (6.25 mM Tris, 10% (v/v) glycerol, 3 mM SDS, 1% beta -mercaptoethanol, 0.75 mM bromphenol blue, pH 6.8) at 95 °C for 3 min. Samples were resolved by 7.5% (w/v) SDS-polyacrylamide gel electrophoresis and electrophoretically transferred to a 0.45-µm Hybond C nitrocellulose membrane (Amersham Corp.).

Immunoblot analysis was performed by incubating the membranes with TBS buffer (50 mM Tris, pH 7.4, containing 150 mM NaCl, 0.1% (v/v) Tween-20 containing 5% (w/v) BSA for 1 h at room temperature followed by incubation with anti-beta -gal antibody (1:500 dilution in TBS buffer) for 1 h at room temperature. The membranes were washed three times with TBS, incubated with horseradish peroxidase-labeled goat anti-rabbit IgG (Bio-Rad) (1:30,000 dilution) for 30 min, and washed three times with TBS, and the proteins were detected using the ECL detection system (Amersham).

Heat Shock Analysis

Heat shock experiments were performed as described previously (4). Briefly, NIH 3T3 cell transfectants were grown on fibronectin-coated plates. The medium was changed to Dulbecco's modified Eagle's medium (serum-free) prior to heat shock, and the cells were incubated at 42 °C for 2 h. The conditioned medium was collected, filtered through a 0.22-µm filter (Corning), activated with 0.1% (w/v) dithiothreitol for 2 h at 37 °C, and processed over a 1-ml heparin-Sepharose-4B (Pharmacia) column equilibrated with 50 mM Tris, pH 7.4, containing 10 mM EDTA (TEB). The column was washed with 50 ml of TEB and eluted with 2.5 ml of 1.5 M NaCl in TEB. The cells were lysed in phosphate-buffered saline containing 1% (v/v) Triton X-100, sonicated for 15 s, clarified by centrifugation at 4 °C, and processed over a heparin-Sepharose-4B column as described previously (5). Both cell lysate and conditioned medium eluates were concentrated through a Centricon 10 (Amicon), resolved by 7.5% (w/v) SDS-polyacrylamide gel electrophoresis, and analyzed by immunoblot analysis using anti-beta -gal antibodies. NIH 3T3 cell transfectants incubated for 2 h at 37 °C were used as controls.


RESULTS AND DISCUSSION

The nomenclature for the human FGF-1 and FGF-2 plasmid discussion utilizes the subscript number to describe the FGF cassette number employed in the construction of the individual reporter gene sequence (10, 11). The residues used to describe the FGF-1 and FGF-2 sequences are based upon the translation of the FGF prototypes as AUG-initiated translation products (1).

We have previously prepared a synthetic human FGF-1 gene by the ligation of four cassettes encoding the FGF-1 ORF (10) and have reported that while the ligation of the FGF-1 NLS, NYKKPK (residues 21-26), to the reporter gene, beta -gal, efficiently translocates the fusion protein, FGF-1(1):beta -gal to the nucleus in transfected NIH 3T3 cells, the FGF-1(1-2-3-4):beta -gal fusion product remains cytosol-associated (Ref. 12, Fig. 1A-D). Because these data suggest that FGF-1 may contain a domain that is able to repress the intracellular function of the FGF-1 NLS, we (i) prepared a series of FGF-1:beta -gal deletion constructs (Fig. 1A), (ii) obtained stable NIH 3T3 cell transfectants, and (iii) assessed the intracellular locale of the reporter gene by immunofluorescence (Fig. 1B), X-gal staining (Fig. 1C), and subcellular fractionation followed by anti-beta -gal immunoblot analysis (Fig. 1D). While the deletion of either cassettes 3 and 4 (residues 84-154) or the deletion of cassette 4 (residues 118-154) does not repress the trafficking of the reporter gene to the nucleus (Fig. 1, A-D), the ligation of cassettes 3 and 4 to the FGF-1 NLS in cassette 1 does repress the trafficking of the reporter gene to the nucleus (Fig. 1, A-D). These data suggest that the carboxyl-terminal half of FGF-1 is involved in the cytosol retention of FGF-1, and residues 84-154 may be important for this function.


Fig. 1. Panel A, schematic representation of FGF-1:beta -gal fusion constructs and the intracellular distribution of the fusion proteins in NIH 3T3 Cells. The plasmid, pMEXneo (25), containing the individual constructs were prepared as described under "Experimental Procedures." The subscript numbers in parentheses refer to the FGF-1 cassette numbers as described (10), and the amino acid residue numbers are shown as subscripts in the bar diagram. The intracellular locale is a summary of the expression data described below. Panel B, intracellular locale of FGF-1:beta -Gal fusion proteins by immunofluorescence. Stable NIH 3T3 cell transfectants were analyzed by immunofluorescence using a polyclonal anti-beta -gal antibody as described (16). The results shown are NIH 3T3 cells transfected with FGF-1(1-2-3-4):beta -gal (A), FGF-1(1-2):beta -gal (B), FGF-1(1-2-3):beta -gal (C), FGF-1(1-4):beta -gal (D), FGF-1(1-3-4):beta -gal (E), and FGF-1(2-3-4):beta -gal (F). Magnification is × 400. Panel C, intracellular locale of FGF-1:beta -gal fusion proteins by beta -gal enzyme activity. The various NIH 3T3 cell transfectants were incubated with X-gal as described under "Experimental Procedures," and the blue complex was examined by light microscopy (magnification × 400). The label of the photomicrograph is identical to that described in Panel B. Panel D, immunoblot analysis of FGF-1:beta -gal fusion proteins in the cytosol and nuclear fractions of NIH 3T3 cells. The various NIH 3T3 cell transfectants were analyzed by cellular fractionation of cytosol and nuclear fractions and beta -gal immunoblot analysis as described under "Experimental Procedures."
[View Larger Version of this Image (43K GIF file)]


In order to determine whether the temperature stress-induced FGF secretion pathway is utilized by FGF-1 and FGF-2, NIH 3T3 cell FGF-1(1-2-3-4):beta -gal and FGF-2(1-2-3-4):beta -gal transfectants (Fig. 2A) were examined for their ability to release the growth factor:reporter gene chimera in response to heat shock. As shown in Fig. 3, A and B, the FGF-1(1-2-3-4):beta -gal, but not the FGF-2(1-2-3-4):beta -gal chimeric protein, was released in response to heat shock as a structurally intact polypeptide with an apparent molecular mass of approximately 118 kDa. These data suggest that the temperature stress-induced pathway is specific for FGF-1 and that this pathway can release FGF-1 as a large molecular weight reporter gene chimeric protein.


Fig. 2. Panel A, schematic representation of the FGF-1, FGF-2, and FGF-1:FGF-2 chimera reporter gene constructs and their intracellular distribution and secretory behavior. The plasmid, pMEXneo (25), containing the individual constructs were prepared as described under "Experimental Procedures." The subscript numbers in parenthesis refer to the cassette numbers. Panel B, beta -gal enzyme staining (X-gal) of the FGF-1:FGF-2:beta -Gal fusion proteins in NIH 3T3 cell transfectants. The various NIH 3T3 cell transfectants were subjected to X-gal staining as described under "Experimental Procedures." A, FGF-1(1-2-3-4):beta -gal; B, FGF-1(1-2-4):FGF-2(3):beta -gal; C, FGF-1(1-2-3):FGF-2(4):beta -gal; D, FGF-1(1-2):FGF-2(3-4):beta -gal; E, FGF-2(1-2-3-4):beta -gal; F, NLS (FGF-2):FGF-1(1-2):FGF-2(3-4):beta -gal; G, NLS (FGF-2):FGF-2(1-2):FGF-1(3-4):beta -gal; H, NLS (FGF-2):FGF-2(1-2-3-4):beta -gal. Magnification is either × 400 (A, B, C, and D) or × 200 (E, F, G, and H). C, beta -gal immunoprecipitation/immunoblot analysis of the FGF-1:FGF-2:beta -Gal fusion proteins from NIH 3T3 cell transfectants. Cytosol and nuclear fractions from the various NIH 3T3 cell lysates were prepared, and immunoprecipitation/immunoblot analysis was performed using an anti-beta -gal antibody as described under "Experimental Procedures."
[View Larger Version of this Image (59K GIF file)]



Fig. 3. Secretion of FGF-1:FGF-2:beta -Gal fusion proteins from NIH 3T3 cell transfectants in response to heat shock. beta -gal immunoblot analysis of NIH 3T3 cell transfectant medium conditioned by heat shock was performed as described under "Experimental Procedures." Control (37 °C) and heat shock (42 °C) samples from lysates (panel A) and conditioned medium (panel B) are shown below the immunoblot.
[View Larger Version of this Image (37K GIF file)]


Because the temperature stress-induced secretion pathway appears to be specific for FGF-1, we used a cassette shuffle strategy to assess whether specific domains are involved in the release of FGF-1. As shown in Fig. 3, A and B, the substitution of either cassette 3 or 4 from FGF-2 for the corresponding cassette in FGF-1 (Fig. 2A) inhibited the release of the FGF-1(1-2-3):FGF-2(4):beta -gal and FGF-1(1-2-4):FGF-2(3):beta -gal chimeric proteins in response to temperature stress from their respective NIH 3T3 cell transfectants. In addition, the introduction of cassettes 3 and 4 from FGF-2 as replacement for their corresponding cassettes in FGF-1 (Fig. 2A) also inhibited the release of FGF-1(1-2):FGF-2(3-4):beta -gal (Fig. 3, A and B). In addition, the majority of stable NIH 3T3 cell transfectants exhibited similar staining as shown in Fig. 2B by X-gal staining and by beta -gal immunofluorescence (data not shown). These data suggest that the domain comprising residues 84-154 from FGF-1 may be involved in the regulation of FGF-1 secretion and that the corresponding domain in FGF-2 is able to repress the release of the FGF reporter gene chimera in response to heat shock.

FGF-2 (17, 18) and FGF-3 (19, 20) are able to utilize alternative 5'-CUG translation initiation start sites, which are able to direct the intracellular traffic of these translation products to the nucleus. Because FGF-1 does not contain this feature (21), we sought to determine whether the FGF-1 cytosol retention domain would repress the ability of the multiple NLS domain encoded by the FGF-2 alternative 5'-CUG translational initiation sequence to traffic FGF-1 to the nucleus. As shown in Fig. 2, B and C, the addition of this multiple NLS domain to the synthetic FGF-2 gene inhibited the ability of the reporter gene to remain cytosol-associated and directed the FGF-2:beta -gal chimeric protein to the nucleus in the NIH 3T3 cell transfectants. Likewise, the replacement of cassettes 1 and 2 in FGF-2 with the corresponding cassettes from FGF-1 also enabled the reporter gene to translocate to the nucleus (Fig. 2, B and C). However, the replacement cassettes 3 and 4 in FGF-2 with the corresponding cassettes from FGF-1 not only inhibited the nuclear traffic of the reporter gene (Fig. 2, B and C) but enabled the chimera to be released from the NIH 3T3 cell transfectants in response to heat shock (Fig. 2D). These data suggest that the domain in FGF-1 responsible for cytosol retention is able to repress the nuclear trafficking properties of the multiple NLS domain present in the alternative 5'-CUG-initiated high molecular weight FGF-2 translation product.

In order to determine whether nuclear-associated FGF-1 is able to access the FGF-1 secretion pathway, an additional construct was prepared in which the entire SV40T ORF was ligated in-frame at the 5'-end of the FGF-1:beta -gal ORF, and the intracellular traffic and stress-induced release of the translation product was assessed. As shown in Figs. 2C and 3, A and B, the SV40T:FGF-1:beta -gal chimera was nucleus-associated and was not released in response to heat shock following expression in NIH 3T3 cells. These data suggest that the domain responsible for FGF-1 cytosol retention may have evolved to ensure participation of FGF-1 in the temperature stress-induced secretion pathway.

The FGF prototype cassette shuffle strategy has enabled us not only to confirm the specificity of the FGF-1 secretion pathway induced by temperature stress (4, 5, 6), but it has also enabled us to determine the importance between the FGF prototype carboxyl-terminal domains as a structural correlate for this specificity. Indeed, the similarities between the FGF prototypes within this domain are accentuated by the ability of these sequences to act as potential cytosol retention domains that are able to repress the function of the NLS in their respective AUG-initiated translation products. However, differences within this domain between the FGF prototypes are revealed by the ability of the FGF-1-derived domain to repress the function of the NLS in the 5'-CUG-initiated translation products and the ability of the FGF-2 domain to repress the release of FGF-1 in response to heat shock. It is also noteworthy that the carboxyl-terminal domain in FGF-1 is involved in the association between FGF-1 and phosphatidylserine (6). Further, our ability to study the secretion of the FGF prototype homologs as chimeric proteins, as well as the inability of FGF-2 to be secreted under conditions where FGF-1 release is readily apparent, serves to reduce concerns relative to the potential artifactual nature of this unconventional, brefeldin A-insensitive (5), stress-induced FGF-1 secretion pathway.

Previous FGF-1 mutagenesis studies have identified the importance of Cys30 in the formation of the stress-induced FGF-1 homodimer (6), and we have proposed that temperature stress may enable Cys30 to gain access to solvent for homodimer formation. Indeed, Cys30 is conserved in FGF-2 (1); yet, interestingly, FGF chimeric proteins containing the carboxyl-terminal domain from FGF-2 also contain Cys30 but are not secreted in response to heat shock. Thus, we suggest that the carboxyl-terminal domain in FGF-2 may prevent solvent accessibility of Cys30 for FGF-2 homodimer formation under temperature stress conditions, and this feature may be involved in determining the specificity between the FGF prototypes for secretion in response to heat shock. This is consistent with the ability of FGF-1 but not FGF-2 to undergo Cu2+-induced homodimer formation (9) and heparin-induced conformational changes (11), although FGF-1 and FGF-2 are both Cu2+-and heparin-binding proteins (9).

The forced nuclear traffic of intracellular FGF-1 by SV40T is also noteworthy, since it was difficult to obtain stable NIH 3T3 cell transfectants using the NLS from either the SV40 large T antigen or histone 2B genes to force the nuclear traffic of intracellular FGF-1 as a result of their diminished proliferative capacity in vitro (data not shown). Indeed, this is consistent with the reports that the nuclear traffic of intracellular FGF-2 (22) and FGF-3 (23) as a result of alternative 5'-CUG translation initiation also results in a reduction of proliferative capacity in vitro and may help explain why the AUG-initiated FGF prototype translation products are localized in the cytosol. Since FGF-1 gains access to the nuclear compartment as a result of its receptor-dependent traffic from the cell surface (12), we suggest that the nuclear traffic of FGF-1 during the entire G1 period of the cell cycle (24) may function, in part, to restrict endocytotic FGF-1 from participation in the FGF-1 secretion pathway.


FOOTNOTES

*   This work was supported by National Institutes of Health Grants HL35627, HL54710, and HL32348 (to T. M.). The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    This work was submitted in partial fulfillment of the requirements for a doctorate of philosophy from the Genetics Graduate Program, Columbian School of Arts and Sciences, George Washington University, Washington, D. C.
§   To whom correspondence should be addressed: Dept. of Molecular Biology, Holland Laboratory, American Red Cross, 15601 Crabbs Branch Way, Rockville, MD 20855. Tel.: 301-738-0653; Fax: 301-738-0465.
1    The abbreviations used are: FGF, fibroblast growth factor; beta -gal, beta -galactosidase; ER, endoplasmic reticulum; NLS, nuclear localization signal; ORF, open reading frame; SV40T, SV40 large T antigen; TBS, Tris-buffered saline; TEB, Tris-buffered EDTA; bp, base pair(s); X-gal, 5-bromo-4-chloro-3-indoyl beta -D-galactoside.

REFERENCES

  1. Burgess, W. H., and Maciag, T. (1989) Annu. Rev. Biochem. 58, 575-606 [CrossRef][Medline] [Order article via Infotrieve]
  2. Friesel, R. E., and Maciag, T. (1995) FASEB J. 9, 919-925 [Abstract/Free Full Text]
  3. Fantl, W. J., Johnson, D. E., and Williams, L. T. (1993) Annu. Rev. Biochem. 62, 453-482 [CrossRef][Medline] [Order article via Infotrieve]
  4. Jackson, A., Friedman, S., Zhan, X., Engleka, K. A., Forough, R., and Maciag, T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10691-10695 [Abstract]
  5. Jackson, A., Tarantini, F., Gamble, S., Friedman, S., and Maciag, T. (1995) J. Biol. Chem. 270, 33-36 [Abstract/Free Full Text]
  6. Tarantini, F., Gamble, S., Jackson, A., and Maciag, T. (1995) J. Biol. Chem. 270, 29039-29042 [Abstract/Free Full Text]
  7. Mach, H., and Middaugh, C. R. (1995) Biochemistry 34, 9913-9920 [Medline] [Order article via Infotrieve]
  8. Mignatti, P., Morimoto, T., and Rifkin, D. B. (1992) J. Cell. Physiol. 151, 81-93 [Medline] [Order article via Infotrieve]
  9. Engleka, K. A., and Maciag, T. (1992) J. Biol. Chem. 267, 11307-11315 [Abstract/Free Full Text]
  10. Forough, R., Engleka, K., Thompson, J. A., Jackson, A., Imamura, T., and Maciag, T. (1991) Biochim. Biophys. Acta 1090, 293-298 [Medline] [Order article via Infotrieve]
  11. Imamura, T., Friedman, S. A., Gamble, S., Tokita, Y., Opalenik, S. R., Thompson, J. A., and Maciag, T. (1995) Biochim. Biophys. Acta 1266, 124-130 [CrossRef][Medline] [Order article via Infotrieve]
  12. Zhan, X., Hu, X. G., Friedman, S., and Maciag, T. (1992) Biochem. Biophys. Res. Commun. 188, 982-991 [Medline] [Order article via Infotrieve]
  13. Forough, R., Zhan, X., MacPhee, M., Friedman, S., Engleka, K. A., Sayers, T., Wiltrout, R. H., and Maciag, T. (1993) J. Biol. Chem. 268, 2960-2968 [Abstract/Free Full Text]
  14. Lin, H.-J., Upson, R. H., and Simmon, D. T. (1992) J. Virol. 66, 5443-5452 [Abstract]
  15. Studier, F. W., Rosenberg, A. H., Dunn, J. J., and Dubendorff, J. W. (1990) Methods Enzymol. 185, 60-89 [Medline] [Order article via Infotrieve]
  16. Wessendorf, J. H. M., Garfinkel, S., Zhan, X., Brown, S., and Maciag, T. (1993) J. Biol. Chem. 268, 22100-22104 [Abstract/Free Full Text]
  17. Bugler, B., Amalric, F., and Prats, H. (1991) Mol. Cell. Biol. 11, 573-577 [Medline] [Order article via Infotrieve]
  18. Florkiewicz, R. Z., and Sommer, A. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3978-3981 [Abstract]
  19. Acland, P., Dixon, M., Peters, G., and Dickson, C. (1990) Nature 343, 662-665 [CrossRef][Medline] [Order article via Infotrieve]
  20. Kiefer, P., Acland, P., Pappin, D., Peters, G., and Dickson, C. (1994) EMBO J. 13, 4126-4136 [Abstract]
  21. Jaye, M., Howk, R., Burgess, W. H., Ricca, G. A., Chiu, I.-M., Ravera, M. W., O'Brien, S. J., Modi, W. S., Maciag, T., and Drohan, W. N. (1986) Science 233, 541-545 [Medline] [Order article via Infotrieve]
  22. Quarto, N., Talarico, D., Florkiewicz, R., and Rifkin, D. B. (1991) Cell Regul. 2, 699-708 [Medline] [Order article via Infotrieve]
  23. Kiefer, P., and Dickson, C. (1995) Mol. Cell. Biol. 15, 4364-4374 [Abstract]
  24. Zhan, X., Hu, X., Friesel, R., and Maciag, T. (1993) J. Biol. Chem. 268, 9611-9620 [Abstract/Free Full Text]
  25. Martin-Zanca, D., Oskam, R., Mitra, G., Copeland, T., and Barbacid, M. (1989) Mol. Cell. Biol. 9, 24-33 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.